Jung W - Search Results

1

Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin's lymphoma.

Wulf GG, Hasenkamp J, Jung W, Chapuy B, Truemper L, Glass B. Wulf GG, et al. Among authors: jung w. Bone Marrow Transplant. 2005 Aug;36(3):271-3. doi: 10.1038/sj.bmt.1705036. Bone Marrow Transplant. 2005. PMID: 15937499 No abstract available.

2

Retroperitoneal fibrosis as manifestation of chronic GVHD after allogeneic hematopoietic SCT.

Dicke C, Kertész A, Henke RP, Hasenkamp J, Jung W, Trümper L, Wulf GG. Dicke C, et al. Among authors: jung w. Bone Marrow Transplant. 2013 Mar;48(3):467-8. doi: 10.1038/bmt.2012.165. Epub 2012 Sep 10. Bone Marrow Transplant. 2013. PMID: 22964591 No abstract available.

3

Resistance against natural killer cell cytotoxicity: analysis of mechanisms.

Hasenkamp J, Borgerding A, Wulf G, Uhrberg M, Jung W, Dingeldein S, Truemper L, Glass B. Hasenkamp J, et al. Among authors: jung w. Scand J Immunol. 2006 Oct;64(4):444-9. doi: 10.1111/j.1365-3083.2006.01803.x. Scand J Immunol. 2006. PMID: 16970688 Free article.

4

Self-tolerance of human natural killer cells lacking self-HLA-specific inhibitory receptors.

Hasenkamp J, Borgerding A, Uhrberg M, Falk C, Chapuy B, Wulf G, Jung W, Trümper L, Glass B. Hasenkamp J, et al. Among authors: jung w. Scand J Immunol. 2008 Mar;67(3):218-29. doi: 10.1111/j.1365-3083.2007.02058.x. Epub 2008 Jan 22. Scand J Immunol. 2008. PMID: 18226015 Free article.

5

Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia.

Schlenk RF, Hartmann F, Hensel M, Jung W, Weber-Nordt R, Gabler A, Haas R, Ho AD, Trümper L, Döhner H. Schlenk RF, et al. Among authors: jung w. Leukemia. 2002 Apr;16(4):581-6. doi: 10.1038/sj.leu.2402423. Leukemia. 2002. PMID: 11960336 Clinical Trial.

6

Increased levels of circulating interleukin-6 in patients with Hodgkin's disease.

Gause A, Scholz R, Klein S, Jung W, Diehl V, Tesch H, Hasenclever D, Pfreundschuh M. Gause A, et al. Among authors: jung w. Hematol Oncol. 1991 Nov-Dec;9(6):307-13. doi: 10.1002/hon.2900090605. Hematol Oncol. 1991. PMID: 1748397

7

[Diagnostics and staging of non-Hodgkin's lymphomas].

Neumann S, Jung W, Trümper L. Neumann S, et al. Among authors: jung w. Internist (Berl). 2007 Apr;48(4):362-71. doi: 10.1007/s00108-007-1824-y. Internist (Berl). 2007. PMID: 17364169 Review. German.

8

Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease.

Gause A, Pohl C, Tschiersch A, Da Costa L, Jung W, Diehl V, Hasenclever D, Pfreundschuh M. Gause A, et al. Among authors: jung w. Blood. 1991 May 1;77(9):1983-8. Blood. 1991. PMID: 1850308 Free article.

9

CD30-antigen-specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: potential use for the treatment of Hodgkin's lymphoma.

Pohl C, Denfeld R, Renner C, Jung W, Bohlen H, Sahin U, Hombach A, van Lier R, Schwonzen M, Diehl V, et al. Pohl C, et al. Among authors: jung w. Int J Cancer. 1993 Jul 9;54(5):820-7. doi: 10.1002/ijc.2910540517. Int J Cancer. 1993. PMID: 7686889

10

Soluble CD8, CD25 and CD30 antigens as prognostic markers in patients with untreated Hodgkin's lymphoma.

Gause A, Jung W, Schmits R, Tschiersch A, Scholz R, Pohl C, Hasenclever D, Diehl V, Pfreundschuh M. Gause A, et al. Among authors: jung w. Ann Oncol. 1992 Sep;3 Suppl 4:49-52. doi: 10.1093/annonc/3.suppl_4.s49. Ann Oncol. 1992. PMID: 1333270

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,221 results

Search Page

Filters